Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.
Gareth J. Morgan, MD, PhD
Advertisement
Articles by Gareth J. Morgan, MD, PhD
Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.
Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Morgan on the Role of Venetoclax in Multiple MyelomaApril 13th 2020
Dr. Morgan on Idecabtagene Vicleucel in Multiple MyelomaApril 16th 2020
Dr. Morgan on BCMA-Targeted ADCs in Multiple MyelomaMarch 17th 2020
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
3
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5